GILD - GILEAD SCIENCES, INC.

QQQ $ 454.82 $ 9.16 (2.02 %)

DIA $ 398.57 $ 1.02 (0.26 %)

SPY $ 530.36 $ 6.28 (1.19 %)

TLT $ 91.26 $ 0.68 (0.73 %)

GLD $ 225.37 $ 2.55 (1.18 %)

Previous Close

$ 63.88

Open

$ 64.39

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 63.34 - $ 64.39

52 Week Range

$ 62.07 - $ 86.97

Volume

6,062,891

Average Volume

Market Cap

79.66B

Beta (5Y Monthly)

$ 0.34

PE Ratio (TTM)

$ 164.24

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.05)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-08-2024	03-31-2024	10-Q
2	02-23-2024	12-31-2023	10-K
3	11-07-2023	09-30-2023	10-Q
4	08-04-2023	06-30-2023	10-Q
5	05-03-2023	03-31-2023	10-Q
6	02-22-2023	12-31-2022	10-K
7	11-02-2022	09-30-2022	10-Q
8	08-08-2022	06-30-2022	10-Q
9	05-04-2022	03-31-2022	10-Q
10	02-23-2022	12-31-2021	10-K
11	11-03-2021	09-30-2021	10-Q
12	08-05-2021	06-30-2021	10-Q
13	05-06-2021	03-31-2021	10-Q
14	02-25-2021	12-31-2020	10-K
15	11-04-2020	09-30-2020	10-Q
16	08-06-2020	06-30-2020	10-Q
17	05-06-2020	03-31-2020	10-Q
18	02-25-2020	12-31-2019	10-K
19	11-05-2019	09-30-2019	10-Q
20	08-06-2019	06-30-2019	10-Q
21	05-08-2019	03-31-2019	10-Q
22	02-26-2019	12-31-2018	10-K
23	11-06-2018	09-30-2018	10-Q
24	08-06-2018	06-30-2018	10-Q
25	05-09-2018	03-31-2018	10-Q
26	02-27-2018	12-31-2017	10-K
27	11-07-2017	09-30-2017	10-Q
28	08-07-2017	06-30-2017	10-Q
29	05-10-2017	03-31-2017	10-Q
30	02-27-2017	12-31-2016	10-K
31	11-07-2016	09-30-2016	10-Q
32	08-05-2016	06-30-2016	10-Q
33	05-06-2016	03-31-2016	10-Q
34	02-24-2016	12-31-2015	10-K
35	11-04-2015	09-30-2015	10-Q
36	08-05-2015	06-30-2015	10-Q
37	05-08-2015	03-31-2015	10-Q
38	02-25-2015	12-31-2014	10-K
39	11-05-2014	09-30-2014	10-Q
40	08-04-2014	06-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Gilead Sciences' Phase 2B MYR204 Open-labe...
06/06/2024 09:23:47

Phase 2b Data Presented at EASL and Published in NEJM Show Potential for Bulevirtide 10 mg in Combination with Pegylated Inte...

100-invested-in-this-stock-20-years-ago-would-be-worth-800-today

$100 Invested In This Stock 20 Years Ago W...
06/05/2024 18:30:32

Gilead's Seladelpar Shows Continued And Re...
06/05/2024 07:34:32

- Positive Results from Two-year Interim Analysis Includes Participants from Phase 3 RESPONSE Study and are Highly Consistent...

national-institutes-of-health-kickstarts-gilead-sponsored-trials-for-twice-yearly-hiv-prevention-injection

National Institutes of Health Kickstarts G...
06/04/2024 19:57:24

The US National Institutes of Health has launched two clinical trials to test a new long-acting form of HIV PrEP in cisgender w...

Gilead Sciences Reaches Agreement In Princ...
06/04/2024 12:37:35

https://www.gilead.com/news-and-press/company-statements/gilead-statement-on-agreement-in-principle-to-resolve-federal-tdf-liti...

after-disappointing-bladder-cancer-data-gilead-announces-encouraging-data-from-gastric-colorectal-cancer-studies

After Disappointing Bladder Cancer Data, G...
06/03/2024 16:35:14

Gilead Sciences and Arcus Biosciences report sustained efficacy and safety in the Phase 2 EDGE-Gastric study for upper GI cance...

$kites-tecartus-shows-40-four-year-overall-survival-rate-in-pivotal-zuma-3-study-for-relapsedrefractory-b-cell-acute-lymphoblastic-leukemia$

Kite's Tecartus Shows 40% Four-Year Overal...
06/03/2024 14:01:56

$kite-a-gilead-company-presents-new-data-on-yescarta-for-relapsedrefractory-central-nervous-system-lymphoma$

Kite, A Gilead Company Presents New Data O...
06/03/2024 13:11:25

-- At Median Follow-Up of 24.2 Months, No Additional Risks of Adverse Events Related to Yescarta Were Observed ---- Findings Al...

Gilead And Arcus Announced Etrumadenant Pl...
06/02/2024 14:36:05

Gilead Sciences, Inc. (NASDAQ:GILD) and Arcus Biosciences, Inc. (NYSE:RCUS) today announced new data from Cohort B of ARC-9, a ...

gileads-trodelvy-fails-to-hit-primary-goal-in-late-stage-study-with-most-common-type-of-bladder-cancer

Gilead's Trodelvy Fails To Hit Primary Goa...
05/31/2024 13:27:46

Gilead Sciences' announced topline results from the Phase 3 TROPiCS-04 study on Trodelvy for metastatic urothelial cancer. ...

Gilead Sciences To Present EVOKE-01 Study ...
05/31/2024 12:16:31

– Simultaneously Published by the Journal of Clinical Oncology –Gilead Sciences, Inc. (NASDAQ:GILD) today announced detailed re...

Gilead Sciences Announces Topline Results ...
05/30/2024 20:45:43

$100 Invested In This Stock 20 Years Ago W...
05/21/2024 21:30:39

gileads-recently-acquired-liver-disease-candidate-shows-improvements-in-disease-progression-and-associated-itch

Gilead's Recently Acquired Liver Disease C...
05/20/2024 13:36:16

Gilead Sciences reports interim results from the ASSURE study of seladelpar in primary biliary cholangitis, showing significant...

Reported Saturday, Gilead Sciences Announc...
05/20/2024 05:59:36

- 70% of Patients Receiving Seladelpar 10mg Achieved the Clinically Meaningful Composite Endpoint and 37% Achieved ALP Normaliz...

market-whales-and-their-recent-bets-on-gild-options

Market Whales and Their Recent Bets on GIL...
05/15/2024 17:46:45

decoding-gilead-sciencess-options-activity-whats-the-big-picture

Decoding Gilead Sciences's Options Activit...
05/10/2024 17:52:29

1000-invested-in-this-stock-20-years-ago-would-be-worth-9300-today

$1000 Invested In This Stock 20 Years Ago ...
05/07/2024 18:30:46

gilead-sciences-unusual-options-activity-for-may-06

Gilead Sciences Unusual Options Activity F...
05/06/2024 19:15:54

how-is-the-market-feeling-about-gilead-sciences

How Is The Market Feeling About Gilead Sci...
05/06/2024 13:15:15

6 Gene Therapy M&A Targets On The Radar
03/27/2019 16:45:40